CytomX Therapeutics' (CTMX) "Market Perform" Rating Reaffirmed at BMO Capital Markets

BMO Capital Markets reaffirmed their market perform rating on shares of CytomX Therapeutics (NASDAQ:CTMX - Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $3.25 target price on the biotechnology company's stock.

CTMX has been the topic of several other reports. StockNews.com cut shares of CytomX Therapeutics from a buy rating to a hold rating in a research report on Tuesday, April 23rd. JPMorgan Chase & Co. upgraded CytomX Therapeutics from an underweight rating to a neutral rating in a report on Monday, April 22nd.

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX traded up $3.50 during midday trading on Wednesday, hitting $5.13. The stock had a trading volume of 205,663,313 shares, compared to its average volume of 3,248,616. The firm has a market cap of $347.45 million, a P/E ratio of -224.14 and a beta of 1.00. The company's 50-day simple moving average is $2.06 and its 200 day simple moving average is $1.65. CytomX Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its quarterly earnings data on Monday, March 11th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.01). The company had revenue of $26.61 million during the quarter, compared to analyst estimates of $23.36 million. Equities analysts expect that CytomX Therapeutics will post -0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 20,223 shares of the business's stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $2.09, for a total transaction of $42,266.07. Following the sale, the chief executive officer now directly owns 524,481 shares of the company's stock, valued at approximately $1,096,165.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 35,024 shares of company stock worth $73,200. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. AlphaMark Advisors LLC boosted its holdings in shares of CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company's stock valued at $36,000 after buying an additional 12,635 shares during the last quarter. Bank of New York Mellon Corp raised its position in CytomX Therapeutics by 737.4% during the third quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company's stock worth $344,000 after acquiring an additional 234,970 shares in the last quarter. Finally, Congress Park Capital LLC lifted its stake in CytomX Therapeutics by 112.8% in the fourth quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company's stock valued at $371,000 after acquiring an additional 126,850 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.